Sorafenib and Bevacizumab Combination Targeted Therapy in Advanced Neuroendocrine Tumor: A Phase II Study of the Spanish Neuroendocrine Tumor Group (GETNE0801)

#280

Introduction: Sorafenib (S) and bevacizumab (B) as single agents have shown efficacy and acceptable toxicity in NETs phase II trials. S+B combination has shown manageable toxicity in phase I trials in solid tumors.

Aim(s): To evaluate the efficacy and toxicity of the combination of S and B in this setting.

Materials and methods: Phase II trial. Eligibility criteria: measurable, non-resectable, histologically confirmed moderately or well-differentiated NETs; one prior chemotherapy allowed; ECOG-PS 0-2. Pts were treated during six months and followed up additional six months. Treatment: S 200mg bid (days one to five of each week) and B 5mg/Kg once every two weeks (day one, week one).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Castellano D, Capdevila J, Salazar R, Sastre J, Alonso V,

Keywords: targeted therapy, sorafenib, bevacizumab,